Clinical Trials Directory

We are doing this study to learn more about Alzheimer's disease and other illnesses of aging (e.g., dementia, mild cognitive impairment [MCI], or other cognition disorders).

We are doing this study to learn more about sleep and body rhythms in children with ADHD. We will use home-based measures, parent reports, and an evening test to see how sleep affects mental health and thinking skills. Dr. Jessica Lunsford-Avery from the Department of Psychiatry is leading this study.

We are doing this study to find out if carefully watching patients with low risk germ cell tumors after surgery will have different results than treating people with chemotherapy afer their surgery. For people who are in standard risk groups related to germ cell tumors, we want to compare the effects of carboplatin with cisplatin and find out which of these drugs seems to work better.

We are doing this study to find out if an experimental drug called efruxifermin (EFX) is a safe and effective option for people who have nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis (scarring of the liver tissue).

We are doing this study to find out if an experimental drug called Lutetium Lu 177 dotatate (the study drug) has the potential to shrink or stabilize bronchial neuroendocrine tumors. We will compare how the study drug works to everolimus, which is the usual drug used for this diagnosis.

We are doing this study to find out if a medical technology called the Signatera blood test can help doctors and patients determine the best course of treatment for bladder cancer after the patient has a radical cystectomy (removal of the bladder and surrounding lymph nodes). The Signatera test is used to detect cancer DNA in the blood before cancer can be seen using imaging (like MRI or CT scans).

This study has two groups based on a test called the Signatera test. People in Group A have a positive test. They will be placed by chance into one of two treatment groups. One group will get a medicine called nivolumab. The other group will get two medicines, nivolumab and relatlimab. These medicines are given through a vein once every 28 days, and people can get up to 12 cycles. People in Group B have a negative test. They will be placed by chance into one of two choices. One choice is to get nivolumab right away, given through a vein once every 28 days for up to 12 cycles. The other choice is close monitoring without starting medicine right away. If their Signatera test changes from negative to positive, they will then be offered nivolumab for up to 12 cycles.

In this study, patients will first receive either the study drug or a placebo for 24 weeks. After that, everyone in the study will receive the real drug for 28 weeks. The whole study will last about 60 weeks. Each person will need to come to the clinic nine times during the study. All visits will take place at the South Durham Clinic.